Portage Biotech Stock Current Valuation
| PRTG Stock | USD 4.41 0.15 3.29% |
Valuation analysis of Portage Biotech helps investors to measure Portage Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The Portage Biotech's current Enterprise Value is estimated to increase to about 365.1 M, while Enterprise Value Over EBITDA is projected to decrease to (14.60). Fundamental drivers impacting Portage Biotech's valuation include:
Undervalued
Today
Please note that Portage Biotech's price fluctuation is extremely dangerous at this time. Calculation of the real value of Portage Biotech is based on 3 months time horizon. Increasing Portage Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Portage stock is determined by what a typical buyer is willing to pay for full or partial control of Portage Biotech. Since Portage Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Portage Stock. However, Portage Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.41 | Real 5.79 | Target 10.0 | Hype 4.26 | Naive 5.48 |
The real value of Portage Stock, also known as its intrinsic value, is the underlying worth of Portage Biotech Company, which is reflected in its stock price. It is based on Portage Biotech's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Portage Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Portage Biotech helps investors to forecast how Portage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Portage Biotech more accurately as focusing exclusively on Portage Biotech's fundamentals will not take into account other important factors: Portage Biotech Company Current Valuation Analysis
Portage Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Portage Biotech Current Valuation | 5.52 M |
Most of Portage Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Portage Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Portage Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Portage Biotech is extremely important. It helps to project a fair market value of Portage Stock properly, considering its historical fundamentals such as Current Valuation. Since Portage Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Portage Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Portage Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Portage Current Valuation Historical Pattern
Today, most investors in Portage Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Portage Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Portage Biotech current valuation as a starting point in their analysis.
Portage Biotech Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Portage Biotech has a Current Valuation of 5.52 M. This is 99.96% lower than that of the Biotechnology sector and 99.88% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Portage Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Portage Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Portage Biotech could also be used in its relative valuation, which is a method of valuing Portage Biotech by comparing valuation metrics of similar companies.Portage Biotech is currently under evaluation in current valuation category among its peers.
Portage Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Portage Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Portage Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Portage Fundamentals
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 5.52 M | ||||
| Shares Outstanding | 1.65 M | ||||
| Shares Owned By Insiders | 29.80 % | ||||
| Shares Owned By Institutions | 17.80 % | ||||
| Number Of Shares Shorted | 19.77 K | ||||
| Price To Book | 5.19 X | ||||
| EBITDA | (18.2 M) | ||||
| Net Income | (75.34 M) | ||||
| Cash And Equivalents | 21.18 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 47 K | ||||
| Current Ratio | 11.73 X | ||||
| Book Value Per Share | 4.07 X | ||||
| Cash Flow From Operations | (14.3 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (68.17) X | ||||
| Target Price | 140.0 | ||||
| Beta | 99.48 | ||||
| Market Capitalization | 7.26 M | ||||
| Total Asset | 7.78 M | ||||
| Retained Earnings | (239.32 M) | ||||
| Working Capital | 4.82 M | ||||
| Net Asset | 7.78 M |
About Portage Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Portage Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Portage Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Portage Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Portage Biotech Piotroski F Score and Portage Biotech Altman Z Score analysis. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.